[{"address1": "88 Sidney Street", "city": "Cambridge", "state": "MA", "zip": "02139", "country": "United States", "phone": "617 649 8600", "website": "https://www.agios.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 383, "companyOfficers": [{"maxAge": 1, "name": "Mr. Brian M. Goff M.B.A.", "age": 54, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 1458975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cecilia  Jones", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 751482, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James William Burns", "age": 45, "title": "Corporate Secretary & Chief Legal Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 1019942, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sarah  Gheuens M.D., Ph.D.", "age": 43, "title": "Chief Medical Officer and Head of Research & Development", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 1247567, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tsveta  Milanova", "age": 46, "title": "Chief Commercial Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 939048, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lewis Clayton Cantley Ph.D.", "age": 74, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1949, "fiscalYear": 2023, "totalPay": 50000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. T. J. Washburn", "age": 41, "title": "VP, Controller & Principal Accounting Officer", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Clive  Patience Ph.D.", "age": 59, "title": "Chief Technical Operations Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher J. M. Taylor", "title": "Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Steven  Vickers", "title": "Vice President of Sales", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 3, "compensationRisk": 4, "shareHolderRightsRisk": 7, "overallRisk": 5, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 47.09, "open": 46.99, "dayLow": 43.54, "dayHigh": 49.36, "regularMarketPreviousClose": 47.09, "regularMarketOpen": 46.99, "regularMarketDayLow": 43.54, "regularMarketDayHigh": 49.36, "beta": 0.783, "forwardPE": -7.4360657, "volume": 874493, "regularMarketVolume": 874493, "averageVolume": 646817, "averageVolume10days": 333230, "averageDailyVolume10Day": 333230, "bid": 45.25, "ask": 45.45, "bidSize": 100, "askSize": 100, "marketCap": 2580670976, "fiftyTwoWeekLow": 19.8, "fiftyTwoWeekHigh": 50.35, "priceToSalesTrailing12Months": 82.43375, "fiftyDayAverage": 45.0216, "twoHundredDayAverage": 32.75855, "currency": "USD", "enterpriseValue": 2075400320, "floatShares": 50374315, "sharesOutstanding": 56893100, "sharesShort": 3455457, "sharesShortPriorMonth": 3191271, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.060700003, "heldPercentInsiders": 0.01551, "heldPercentInstitutions": 1.04041, "shortRatio": 6.7, "shortPercentOfFloat": 0.0616, "impliedSharesOutstanding": 56893100, "bookValue": 11.613, "priceToBook": 3.9059675, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -364931008, "trailingEps": -6.5, "forwardEps": -6.1, "pegRatio": -0.24, "enterpriseToRevenue": 66.294, "enterpriseToEbitda": -5.2, "52WeekChange": 0.71673346, "SandP52WeekChange": 0.24059486, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AGIO", "underlyingSymbol": "AGIO", "shortName": "Agios Pharmaceuticals, Inc.", "longName": "Agios Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1374672600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "52f076ec-0de6-382e-b01b-3ddfa165dcb4", "messageBoardId": "finmb_46539787", "gmtOffSetMilliseconds": -14400000, "currentPrice": 45.36, "targetHighPrice": 60.0, "targetLowPrice": 52.0, "targetMeanPrice": 56.0, "targetMedianPrice": 56.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 569891968, "totalCashPerShare": 10.017, "ebitda": -399096000, "totalDebt": 64620000, "quickRatio": 9.158, "currentRatio": 10.092, "totalRevenue": 31306000, "debtToEquity": 9.783, "revenuePerShare": 0.557, "returnOnAssets": -0.27247998, "returnOnEquity": -0.44922, "freeCashflow": -223510368, "operatingCashflow": -306587008, "revenueGrowth": 0.284, "operatingMargins": -12.28288, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-29"}]